Title:
PROMOTER FOR INDUCING DIFFERENTIATION INTO INSULIN-PRODUCING CELLS
Document Type and Number:
WIPO Patent Application WO/2018/128177
Kind Code:
A1
Abstract:
The purpose of the present invention to provide a method/means for more efficiently inducing differentiation into insulin-producing cells, in a system for inducing differentiation from pluripotent stem cells, such as iPS cells, into insulin-producing cells. A compound having an ABL1 tyrosine kinase inhibitory effect serves to promote the induction of differentiation from pluripotent stem cells into insulin-producing cells, and thus can be used as an agent for inducing differentiation into insulin-producing cells.
Inventors:
KONISHI ATSUSHI (JP)
HARADA ERI (JP)
ONUKI HAJIME (JP)
HARADA ERI (JP)
ONUKI HAJIME (JP)
Application Number:
PCT/JP2018/000019
Publication Date:
July 12, 2018
Filing Date:
January 04, 2018
Export Citation:
Assignee:
AJINOMOTO KK (JP)
International Classes:
C12N5/077; C12N5/0735; C12N5/10
Domestic Patent References:
| WO2010051223A1 | 2010-05-06 |
Other References:
XIA C. Q. ET AL.: "C-Abl inhibitor imatinib enhances insulin production by beta cells: c-abl negatively regulates insulin production via interfering with the expression of NKx2. 2 and GLUT-2", PLOS ONE, vol. 9, no. 5, 16 May 2014 (2014-05-16), pages 1 - 11, XP055511718
MOKHTARI D. ET AL.: "Imatinib mesilate-induced phosphatidylinositol 3-kinase signalling and improved survival in insulin-producing cells: role of Src homology 2-containing inositol 5'-phosphatase interaction with c-Abl", DIABETOLOGIA, vol. 56, no. 6, June 2013 (2013-06-01), pages 1327 - 1338, XP055179409
HENKES M. ET AL.: "Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevec)", THERAPEUTICS AND CLINICAL RISK MANAGE,, vol. 4, no. 1, February 2008 (2008-02-01), pages 163 - 187, XP009142188
AGAMI R. ET AL.: "The kinase activity of c-Abl but not v-Abl is potentiated by direct interaction with RFXI , a protein that binds the enhancers of several viruses and cell -cycle regulated genes", ONCOGENE, vol. 16, no. 14, 9 April 1998 (1998-04-09), pages 1779 - 1788
FU Z. ET AL.: "Genistein induces pancreatic beta- cell proliferation through activation of multiple signaling pathways and prevents insulin-deficient diabetes in mice", ENDOCRINOLOGY, vol. 151, no. 7, July 2010 (2010-07-01), pages 3026 - 3037
MOKHTARI D. ET AL.: "Imatinib mesilate-induced phosphatidylinositol 3-kinase signalling and improved survival in insulin-producing cells: role of Src homology 2-containing inositol 5'-phosphatase interaction with c-Abl", DIABETOLOGIA, vol. 56, no. 6, June 2013 (2013-06-01), pages 1327 - 1338, XP055179409
HENKES M. ET AL.: "Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevec)", THERAPEUTICS AND CLINICAL RISK MANAGE,, vol. 4, no. 1, February 2008 (2008-02-01), pages 163 - 187, XP009142188
AGAMI R. ET AL.: "The kinase activity of c-Abl but not v-Abl is potentiated by direct interaction with RFXI , a protein that binds the enhancers of several viruses and cell -cycle regulated genes", ONCOGENE, vol. 16, no. 14, 9 April 1998 (1998-04-09), pages 1779 - 1788
FU Z. ET AL.: "Genistein induces pancreatic beta- cell proliferation through activation of multiple signaling pathways and prevents insulin-deficient diabetes in mice", ENDOCRINOLOGY, vol. 151, no. 7, July 2010 (2010-07-01), pages 3026 - 3037
Attorney, Agent or Firm:
TAKASHIMA, Hajime et al. (JP)
Download PDF: